Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00428948 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1445

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycystic Kidney Disease, Autosomal Dominant

Interventions

DRUG: Tolvaptan
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

[object Object]